Tetrous
EnFix TAC™
EnFix TAC-T

TAC-T

EnFix TAC-O

TAC-O

EnFix RC™

For use with suture anchors

SOLE RECIPIENT OF THE 2024 AOSSM ACE AWARD

Biologic solutions to optimize enthesis reformation, EnFix is the future of bone to tendon healing.

IT’S ALL ABOUT THE ENTHESIS™

EnFix TAC® Procedure

EnFix® is specifically designed to address Enthesis Failure Syndrome by promoting the remodeling of tissue approximating that of the natural bone-tendon enthesis.

Our technology has a successful clinical legacy and has been extensively studied in bone and tendon healing demonstrating both osteoconductivity and osteoinductivity. The demineralized bone fibers in EnFix® promote optimal biologic performance while easily integrating into current surgical techniques.

The Bone Textile™ technology yields long and strong fibers that promote cell wicking, cell adhesion and cell proliferation, versus the highly variable short shavings that are produced by other processes. The FormLok™ technology imparts shape retention to the device, even when immersed in liquid, as is often required for use in arthroscopic surgery.

Understanding the Enthesis
Andy Carter, PhD. presents "Understanding the Enthesis"

Andy Carter, PhD.
Co-Founder and Chief Technology Officer,
Tetrous, Inc.

View Full Presentation
Bone to Tendon Healing
Nik Verma presents Bone to Tendon Healing at AOSSM

Nik Verma, MD.
Professor and Director
Sports Medicine and Shoulder
Midwest Orthopedics at Rush
Head Team Physician,
Chicago White Sox

View Nik Verma's Full AOSSM talk
The Holy Grail
Tito's AOSSM Talk on the "Holy Grail of Bone Healing"

Ferdinand “Tito” Liotta, MD.
Orthopedic Surgeon & Sports Medicine Physician
Valley View Health
Glenwood Springs, CO

View Tito's Full AOSSM talk

Rotator Cuff Market

$3 Billion

In the United States alone, more than 500,000 rotator cuff repairs (RCR) are performed annually at a cost of $3 billion.

20% to 70%

20% to 70% of RCRs structurally fail. This failure rate is likely to rise given an aging population with greater functional demands.

RCR Augmentation

Most augmentation products have focused on overlays / patches to reinforce the tendon.

Tetrous has flipped the script by developing methods to enhance healing at the tendon-to-bone interface

The enthesis is where failures often occur in sports medicine repairs.  Tendon reattachment to the bone is a crucial clinical need, especially in larger tears, since failure rates increase linearly with tear size.

Follow Us On LinkedIn
Tetrous

© Tetrous, Inc. All rights reserved.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous.

Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions.

Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women.

Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.

Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous. Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions. Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women. Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum. Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.